Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- المؤلفون: Fransén Pettersson, Nina1; Deronic, Adnan1; Nilsson, Julia1; Hannibal, Tine D.1; Hansen, Lisbeth1; Schmidt-Christensen, Anja1; Ivars, Fredrik1; Holmberg, Dan1
- المصدر:
PLoS ONE. 9/5/2018, Vol. 13 Issue 9, p1-14. 14p.
- الموضوع:
- معلومة اضافية
- نبذة مختصرة :
Quinoline-3-carboxamides (Q substances) are small molecule compounds with anti-inflammatory properties. In this study, we used one of these substances, Paquinimod, to treat a novel model for chronic liver inflammation and liver fibrosis, the NOD-Inflammation Fibrosis (N-IF) mouse. We show that treatment of N-IF mice significantly reduced inflammation and resulted in the regression of fibrosis, even when the treatment was initiated after onset of disease. The reduced disease phenotype was associated with a systemic decrease in the number and reduced activation of disease-promoting transgenic natural killer T (NKT)-II cells and their type 2-cytokine expression profile. Paquinimod treatment also led to a reduction of CD115+ Ly6Chi monocytes and CD11b+ F4/80+ CD206+ macrophages. [ABSTRACT FROM AUTHOR]
No Comments.